Showing results (21-30 of 123) with videos related to

Sort By:
Pageof 13
AIDS (London, England)|October 30, 2009
Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasetsLambert Assoumou, Alessandro Cozzi-Lepri, Françoise Brun-Vézinet, et al.
Substance Abuse Treatment, Prevention, and Policy|August 25, 2025
Differences between men who have sex with men that use drugs and engage in chemsex and those who do not engage in chemsex in the French ANRS-PREVENIR cohort: the need to rethink harm reduction servicesLuis Sagaon-Teyssier, Maxime Hoyer, Cécile Donadille, et al.
The Journal of Antimicrobial Chemotherapy|July 22, 2008
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 TrialClaudine Duvivier, Jade Ghosn, Lambert Assoumou, et al.
AIDS (London, England)|June 3, 2009
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trialCathia Soulié, Lambert Assoumou, Jade Ghosn, et al.
AIDS (London, England)|August 11, 2020
Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirineLambert Assoumou, Chrystèle Racine, Soraya Fellahi, et al.
AIDS (London, England)|January 6, 2016
Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoirRuxandra Calin, Chiraz Hamimi, Sidonie Lambert-Niclot, et al.
AIDS (London, England)|February 13, 2025
Use of doravirine-based regimens in clinical practice in EuropeAgathe Rami, Anton L Pozniak, Lambert Assoumou, et al.
AIDS (London, England)|October 22, 2010
Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patientsAna Canestri, Anne Krivine, Lambert Assoumou, et al.
AIDS (London, England)|April 8, 2021
Altered subcutaneous adipose tissue parameters after switching ART-controlled HIV+ patients to raltegravir/maravirocJean-Philippe Bastard, Véronique Pelloux, Rohia Alili, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 5, 2015
Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral TherapyLaurence Weiss, Mathieu F Chevalier, Lambert Assoumou, et al.
Pageof 13